Abstract:Melanoma is a cancer that is metastatic, drug-refractory and fatal if managed late or inadequately. The transcription factor E2F1 is a key player in melanoma pathology, promoting metastatic traits like EMT, neoangiogenesis, chemoresistance and evasion of immune surveillance. Particularly, high levels of E2F1 trigger tumor progression by developing protein-protein interactions (PPI) with coregulators that enhance its potential to activate a prometastatic gene regulatory network (GRN). We aimed to investigate the extent to which E2F1-expressing melanoma cells influence the immune response. Methods: We combined transcriptomic approaches with bioinformatics and structural modeling to search for target genes involved in E2F1-activated immunomodulatory and prometastatic GRNs in aggressive melanoma. Immunoprecipitation and ChIP were performed to verify both PPI and protein-DNA interactions. Functional analyses, including qRT-PCR, immunoblotting and luciferase assays, were performed to verify expression and regulation of downstream targets. Additionally, we established a melanoma-immune cell coculture system with patient-derived CD4+ and CD8+ T cells. Cytokine arrays and ELISA were used for measurement of cytokine secretion to analyze the E2F1-induced tumor-immuno-crosstalk. Results: We identified an E2F1-dependent GRN with IL-6 as a central factor mediating EMT and immune regulation. Mechanistically, E2F1-induced activation and secretion of IL-6 leads to an autocrine inflammatory forward-feedback loop, which in turn further promotes invasiveness and EMT marker expression in melanoma cells. Interestingly, IL6 activated STAT3 associates with E2F1 in a structure-dependent manner, forming a complex that enhances IL-6 expression by binding to a composite E2F1:STAT3-responsive promoter element. Moreover, we observed that the E2F1-IL6 axis dispenses immunomodulatory effects on surrounding CD4+ and CD8+ T cells, further stimulating IL-6 release, but also leading to secretion of IL-10 into the TME. Although IL-10 has an immunosuppressive function, it also showed anti-metastatic properties in melanoma cells. Thus, in contrast to IL-6, IL-10 decreased cell motility and reduced the expression of Vim, Slug, and Snai1, while simultaneous knockdown of E2F1 increased these effects. The findings are supported by clinical data sets showing that melanoma patients who have high levels of E2F1 and IL-6 and low IL-10 exhibit poor survival. Conclusion: Our results unveil a novel gene regulatory program by which E2F1-associated IL-6 release induces the formation of an E2F1:STAT3 complex, resulting in a forward-feedback loop that promotes cancer invasion and regulates T cells response through intercellular cytokine signaling in the tumor microenvironment. Citation Format: Prabir Dhar, Krishna P. Singh, Shailendra K. Gupta, Dhanya Peringot, Alf Spitschak, Brigitte M. Pützer. E2F1-induced autocrine IL-6 inflammatory loop mediates cancer-immune cell crosstalk that regulates metastatic properties in melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6814.

Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression

Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis

Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma

Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers

Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy

S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling

NLRP3 Suppresses NK Cell–Mediated Responses to Carcinogen-Induced Tumors and Metastases

Soluble NKG2D Ligand Promotes MDSC Expansion and Skews Macrophage to the Alternatively Activated Phenotype.

The Inflammasome Component Nlrp3 Impairs Antitumor Vaccine by Enhancing the Accumulation of Tumor-Associated Myeloid-Derived Suppressor Cells

Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells

Abstract 6814: E2F1-induced autocrine IL-6 inflammatory loop mediates cancer-immune cell crosstalk that regulates metastatic properties in melanoma

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis

IL-12 Enhances Immune Response by Modulation of Myeloid Derived Suppressor Cells in Tumor Microenvironment

Myeloid-derived suppressor cells as regulators of the immune system

NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma

Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway

Interleukin-1beta Triggers the Expansion of Circulating Granulocytic Myeloid-Derived Suppressor Cell Subset Dependent on Erk1/2 Activation

Host-derived Interleukin 1α induces an immunosuppressive tumor microenvironment via regulating monocyte-to-macrophage differentiation